Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome

Clinical Cancer Research

Volumn 10, Issue 16, 2004, Pages 5342-5348

  Wiedswang, Gro ^a   Borgen, Elin ^a   Kåresen, Rolf ^a   Qvist, Hanne ^a   Janbu, Jan ^b   Kvalheim, Gunnar ^a   Nesland, Jahn M ^a   Naume, Bjørn ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b VESTRE VIKEN HOSPITAL TRUST   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN;

ADULT; ARTICLE; BONE MARROW BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; ISOLATED TUMOR CELL; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; TUMOR CELL;

BIOPSY, NEEDLE; BONE MARROW CELLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 4143134311     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0245     Document Type: Article

References (26)

1. Mansi JL, Easton D, Berger U, Gazet, et al. Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years' follow-up. Eur J Cancer 1991;27:1552-5.
2. Harbeck N, Untch M, Pache L, Eiermann W. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up. Br J Cancer 1994 69:566-71,
3. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991;9:1749-56.
4. Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996;88:1652-8.
5. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000;342:525-33.
6. Gebauer G, Fehm T, Merkle E, et al. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 2001;19:3669-74.
7. Wiedswang G, Borgen E, Kåresen R, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003;21:3469-78.
8. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-42.
9. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351:1451-67.
10. Braun S, Kentenich C, Janni W, et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 2000;18: 80-6.
11. Janni W, Hepp F, Rjosk D, et al. The late and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer 2001;92: 46-53.
12. Naume B, Borgen E, Kvalheim G, et al. Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics. Clin Cancer Res 2001;7:4122-9.
13. Borgen E, Naume B, Nesland JM, et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood: establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999;1:377-88.
14. Naume B, Wiedswang G, Borgen E, et al. The prognostic value of isolated tumour cells in bone marrow in breast cancer patients. Evaluation of morphological categories and the number of clinically significant cells. Clin Cancer Res 2004;10:3091-7.
15. Borgen E, Naume B, Nesland JM, et al. Use of automated microscopy for the detection of disseminated tumor cells in bone marrow samples. Cytometry 2001;46:215-21.
16. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19: 403-10.
17. Goss P, Ingle JN, Martino S, et al. Randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 2003;349:1793-1802.
18. Coombes RC, Hall E, Gibson L, et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350: 1081-92.
19. Pantel K, Otte M. Identification and characterisation of minimal residual disease in solid tumors. Acta Med Austriaca 2000;27(Suppl 52):8-12.
20. Braun S, Schlimok G, Heumos I, et al. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 2001;61:1890-5.
21. Allgayer H, Heiss MM, Riesenberg R, et al. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res 1997;57: 1394-9.
22. Mansi JL, Berger MS, McDonnell CO, et al. The fate of bone marrow micrometastasis in patients with primary breast cancer. J Clin Oncol 1989;7:445-9.
23. Molino A, Pelosi G, Micciolo R, et al. Bone marrow micrometastases in breast cancer patients. Breast Cancer Res Treat 1999;58:123-30.
24. Molino A, Pelosi G, Turazza M, et al. Bone marrow micrometastases in 109 breast cancer patients: correlations with clinical and pathological features and prognosis. Breast Cancer Res Treat 1997;42: 23-30.
25. Hempel P, Muller P, Oruzio D, et al. Combination of high-dose chemotherapy and monoclonal antibody in breast-cancer patients: a pilot trial to monitor treatment effects on disseminated tumor cells. Cytotherapy 2000;2:287-95.
26. Kasimir-Bauer S, Mayer S, Bojko P, et al. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy. Clin Cancer Res 2001;7:1582-9.